Regulus Therapeutics Inc

NASDAQ:RGLS   3:55:08 PM EDT
1.75
-0.01 (-0.57%)
Products, Regulatory

Regulus Therapeutics Announces Positive Topline Safety And Pharmacokinetic Data From The Phase 1 Single-Ascending Dose Clinical Trial

Published: 09/12/2022 13:25 GMT
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (pk) Data From the Phase 1 Single-ascending Dose (sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (adpkd).
Regulus Therapeutics Inc - Phase 1b Multiple Ascending Dose (mad) Study Initiated.
Regulus Therapeutics Inc - Rgls8429 in Healthy Volunteers Was Well-tolerated With Dose-proportional Pk.
Regulus Therapeutics Inc - Topline Data From First Cohort of Patients With Adpkd Anticipated in 1h 2023.